Dry eye disease affects many people across different autoimmune diseases, ranging in prevalence from about 23% to 81%, and appears about 3 years before diagnosis, a study finds. Medscape Medical News
Uncategorized
FDA introduces new approval process for rare disease therapies
The FDA has introduced a new approval process for targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra rare diseases in which randomized controlled trials are not feasible.HHS Secretary R…
Uncategorized
FDA introduces new approval process for rare disease therapies
The FDA has introduced a new approval process for targeted individualized therapies, including genome editing and RNA-based therapies, intended to treat rare and ultra rare diseases in which randomized controlled trials are not feasible.HHS Secretary R…
Uncategorized
Tecnis Odyssey IOL encouraging in nontraditional patients
WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2026, Carlton Yuen, MD, discusses his experience with the Tecnis Odyssey full visual range IOL.Yuen, of Aloha Vision Consultants, said the Tecnis Odyssey (Johnson & Johnson) provides…
Uncategorized
Tecnis Odyssey IOL encouraging in nontraditional patients
WAIKOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2026, Carlton Yuen, MD, discusses his experience with the Tecnis Odyssey full visual range IOL.Yuen, of Aloha Vision Consultants, said the Tecnis Odyssey (Johnson & Johnson) provides…
AGS 2026
Read clinically focused news coverage of key developments from AGS 2026 Medscape Ophthalmology